Evidence map›Paper›PMID 38466467›Full record

ArticleMolecular and cellular biochemistry2025

Nicaraven attenuates the acquired radioresistance of established tumors in mouse models via PARP inhibition.

Kai Huang, Chen Yan, Lina Abdelghany, Xu Zhang, Keiichi Jingu, Tao-Sheng Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kai HuangDepartment of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Chen YanDepartment of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Lina AbdelghanyDepartment of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Xu ZhangDepartment of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Keiichi JinguDepartment of Radiation Oncology, Graduate School of Medicine, Tohoku University, 2-1 Seiryomachi, Aoba Ward, Sendai, Miyagi, 980-0872, Japan.
Tao-Sheng LiDepartment of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. litaoshe@nagasaki-u.ac.jp.

Funding

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science JP22K07749Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science JP22K20795
6 · The paper itself

Abstract

Nicaraven has been reported to inhibit the activity of poly (ADP-ribose) polymerase (PARP). In this study, we investigated the probable ability of nicaraven to attenuate cancer radioresistance during fractionated radiotherapy. Tumor models were established in C57BL/6 mice and BALB/c nude mice by subcutaneous injection of Lewis mouse lung carcinoma cancer cells and A549 human lung cancer cells, respectively. When the tumors had grown to approximately 100 mm

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsRadiation ToleranceA549 CellsAnimalsCarcinoma, Lewis LungCell Line, TumorHumansLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLMice, NudePoly(ADP-ribose) PolymerasesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAcquired radioresistanceNicaravenPARP inhibitionRadiation

Identifiers

PMID38466467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.